| 摘要 |
The invention is concerned with novel heterocyclyl compounds of formula (I), wherein A, X, Y, R, R, R, R, R, R, R, R, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.
|
